- Trials with a EudraCT protocol (493)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
493 result(s) found for: Cervical Cancer AND Cancer.
Displaying page 5 of 25.
| EudraCT Number: 2008-008124-33 | Sponsor Protocol Number: 112024 | Start Date*: 2009-10-07 |
| Sponsor Name:GlaxoSmithKline Biologicals | ||
| Full Title: A phase IIIb, open, multi centre gynaecological extension study for follow-up of a subset of 580299/008 study subjects who were either cervical cytology negative and oncogenic HPV positive or pregn... | ||
| Medical condition: GSK Biologicals’ HPV-16/18 L1 VLP AS04 vaccine is indicated in females from 10 years of age onwards for the prevention of cervical cancer (squamous-cell carcinoma and adenocarcinoma) by protecting ... | ||
| Disease: | ||
| Population Age: Adults | Gender: Female | |
| Trial protocol: FI (Completed) ES (Completed) DE (Completed) GB (Completed) | ||
| Trial results: View results | ||
| EudraCT Number: 2020-004873-29 | Sponsor Protocol Number: SGNTUC-019 | Start Date*: 2021-05-31 | ||||||||||||||||||||||||||||||||||||||||||||||
| Sponsor Name:Seagen Inc. | ||||||||||||||||||||||||||||||||||||||||||||||||
| Full Title: A Phase 2 Basket Study of Tucatinib in Combination with Trastuzumab in Subjects with Previously Treated, Locally Advanced Unresectable or Metastatic Solid Tumors Driven by HER2 Alterations | ||||||||||||||||||||||||||||||||||||||||||||||||
| Medical condition: Previously Treated, Locally-Advanced Unresectable or Metastatic Solid Tumors Driven by HER2 Alterations | ||||||||||||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||||||||||||||||||||||||||||||||
| Trial protocol: BE (Trial now transitioned) NL (Ongoing) DE (Trial now transitioned) PL (Completed) IT (Completed) | ||||||||||||||||||||||||||||||||||||||||||||||||
| Trial results: (No results available) | ||||||||||||||||||||||||||||||||||||||||||||||||
| EudraCT Number: 2019-003486-17 | Sponsor Protocol Number: 9-VPH-MVIH | Start Date*: 2020-02-11 |
| Sponsor Name:CARMEN HIDALGO TENORIO | ||
| Full Title: Immunogenicity and safety of a 9-valent human papillomavirus vaccine in HIV-positive women | ||
| Medical condition: New infection and lesions of papillomavirus in HIV-infected women | ||
| Disease: | ||
| Population Age: Adults | Gender: Female | |
| Trial protocol: ES (Ongoing) | ||
| Trial results: (No results available) | ||
| EudraCT Number: 2010-021502-38 | Sponsor Protocol Number: LO-10-02 | Start Date*: 2011-01-25 | ||||||||||||||||
| Sponsor Name:Christine Fromer Stiftung | ||||||||||||||||||
| Full Title: STUDIE ZUR MESSUNG DER VAGINALEN INTERLEUKINE BEI PATIENTINNEN MIT ZERVIKALEN NEOPLASIEN (CIN 1-3) ODER CHRONISCHER CANDIDIASIS VAGINALIS UNTER BEHANDLUNG MIT 4PHENYL-BUTYRATE | ||||||||||||||||||
| Medical condition: Patienten mit diagnostizierter cervikaler Neoplasie (CIN1-3) oder chronisch - rezidivierender Vaginalcandidiasis | ||||||||||||||||||
|
||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Female | |||||||||||||||||
| Trial protocol: DE (Prematurely Ended) | ||||||||||||||||||
| Trial results: (No results available) | ||||||||||||||||||
| EudraCT Number: 2016-000547-14 | Sponsor Protocol Number: BGOG-cx3 | Start Date*: 2017-08-30 | |||||||||||
| Sponsor Name:BGOG-UZLeuven | |||||||||||||
| Full Title: BGOG-cx3: Prospective randomized Phase II trial comparing doxorubicin alone versus doxorubicin and atezolizumab in recurrent cervical cancer | |||||||||||||
| Medical condition: recurrent cervical cancer | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Female | ||||||||||||
| Trial protocol: BE (Completed) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2016-002243-42 | Sponsor Protocol Number: GCT1021-01 | Start Date*: 2016-10-25 | ||||||||||||||||||||||||||||||||||||||||||||||
| Sponsor Name:Genmab A/S | ||||||||||||||||||||||||||||||||||||||||||||||||
| Full Title: First-in-human, open-label, dose-escalation trial with expansion cohorts to evaluate safety of Axl-specific antibody-drug conjugate (enapotamab vedotin, HuMax®-AXL-ADC) in patients with solid tumors. | ||||||||||||||||||||||||||||||||||||||||||||||||
| Medical condition: Cancer of the ovary, cervix, endometrium, anaplastic thyroid, lung (non-small cell lung cancer [NSCLC]) or melanoma | ||||||||||||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||||||||||||||||||||||||||||||||
| Trial protocol: DK (Completed) | ||||||||||||||||||||||||||||||||||||||||||||||||
| Trial results: View results | ||||||||||||||||||||||||||||||||||||||||||||||||
| EudraCT Number: 2019-004050-29 | Sponsor Protocol Number: Vvax001-UMCG-02 | Start Date*: 2020-03-30 |
| Sponsor Name:University Medical Center Groningen | ||
| Full Title: A phase II study to determine the efficacy and safety of Vvax001, a therapeutic Semliki Forest Virus based cancer vaccine, in patients with HPV-16 induced grade 3 cervical intraepithelial neoplasia. | ||
| Medical condition: HPV-16 induced pre malignant cervical lesions | ||
| Disease: | ||
| Population Age: Adults | Gender: Female | |
| Trial protocol: NL (Completed) | ||
| Trial results: (No results available) | ||
| EudraCT Number: 2021-006543-10 | Sponsor Protocol Number: XB002-101 | Start Date*: 2023-03-27 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Sponsor Name:Exelixis, Inc. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Full Title: A dose-escalation and expansion study of the safety and pharmacokinetics of XB002 as single-agent and combination therapy in subjects with inoperable locally advanced or metastatic solid tumors | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Medical condition: Advanced solid tumors for whom life-prolonging therapies do not exist or available therapies are intolerable or no longer effective. Single-agent XB002 will be evaluated up to 10 tumor types, and c... | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Trial protocol: ES (Ongoing) FR (Trial now transitioned) | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Trial results: (No results available) | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| EudraCT Number: 2013-001699-39 | Sponsor Protocol Number: HER117158 | Start Date*: 2015-03-11 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Sponsor Name:GlaxoSmithKline Research Development Ltd | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Full Title: A phase I, first time in human, open-label, dose escalation study to investigate the safety, pharmacokinetics, and pharmacodynamics of anti-HER3 monoclonal antibody GSK2849330 in subjects with adva... | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Medical condition: Subjects with advanced HER3-positive solid tumors | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Trial protocol: NL (Completed) | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Trial results: View results | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| EudraCT Number: 2017-003102-40 | Sponsor Protocol Number: M17CPF | Start Date*: 2018-11-01 | |||||||||||
| Sponsor Name:NKI-AVL | |||||||||||||
| Full Title: Neo-Adjuvant Chemotherapy and Conservative Surgery in Cervical Cancer to Preserve Fertility | |||||||||||||
| Medical condition: women ≥18 and ≤ 40 years with FIGO stage Ib1 cervical carcinoma with tumor measuring ≥ 2 cm and ≤ 4 cm on physical examination and imaging | |||||||||||||
|
|||||||||||||
| Population Age: Adults | Gender: Female | ||||||||||||
| Trial protocol: NL (Prematurely Ended) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2006-004933-14 | Sponsor Protocol Number: V502-003-01 | Start Date*: 2006-11-13 | |||||||||||
| Sponsor Name:Merck & Co., Inc. | |||||||||||||
| Full Title: A Randomized, International, Double-Blinded (With In-House Blinding), Controlled With GARDASIL™, Tolerability, Immunogenicity, and Efficacy Study of a Second Generation Human Papillomavirus (HPV) L... | |||||||||||||
| Medical condition: Prevention of cervical, vulvar, and vaginal cancers and related precancers, external genital lesions, and persistent infection caused by Human Papillomavirus (HPV) 6, 11, 16, 18, 31, 45, 52, and 58. | |||||||||||||
|
|||||||||||||
| Population Age: Adolescents, Under 18, Adults | Gender: Female | ||||||||||||
| Trial protocol: DK (Prematurely Ended) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2021-003871-32 | Sponsor Protocol Number: AL3818-US-002 | Start Date*: 2021-11-11 | ||||||||||||||||||||||||||
| Sponsor Name:ADVENCHEN LABORATORIES, LLC | ||||||||||||||||||||||||||||
| Full Title: A Phase 1/2a/3 Evaluation of the Safety and Efficacy of Adding AL3818 (Anlotinib, INN: Catequentinib), a Dual Receptor Tyrosine Kinase Inhibitor, to Standard Platinum-Based Chemotherapy in Subjects... | ||||||||||||||||||||||||||||
| Medical condition: Recurrent or metastatic endometrial, ovarian, fallopian tube, primary peritoneal, or cervical carcinoma. | ||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Female | |||||||||||||||||||||||||||
| Trial protocol: ES (Ongoing) IT (Trial now transitioned) | ||||||||||||||||||||||||||||
| Trial results: (No results available) | ||||||||||||||||||||||||||||
| EudraCT Number: 2019-003152-37 | Sponsor Protocol Number: MK3475-A18/ENGOT-cx11/GOG-3047 | Start Date*: 2020-05-28 | |||||||||||
| Sponsor Name:Merck Sharp & Dohme Corp., a subsidiary of Merck &Co.,Inc | |||||||||||||
| Full Title: A Randomized, Phase 3, Double-Blind Study of Chemoradiotherapy With or Without Pembrolizumab for the Treatment of High-risk, Locally Advanced Cervical Cancer (KEYNOTE-A18 / ENGOT-cx11/GOG-3047) | |||||||||||||
| Medical condition: High-risk locally advanced cervical cancer | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Female | ||||||||||||
| Trial protocol: NO (Trial now transitioned) HU (Trial now transitioned) CZ (Trial now transitioned) ES (Ongoing) FR (Trial now transitioned) IE (Trial now transitioned) SE (Trial now transitioned) DE (Trial now transitioned) GR (Trial now transitioned) IT (Trial now transitioned) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2018-003756-20 | Sponsor Protocol Number: ENGOT-Cx7-NSGO/MaRuC | Start Date*: 2019-10-08 | |||||||||||||||||||||||||||||||
| Sponsor Name:Nordic Society of Gynaecological Oncology-Clinical Trial Unit | |||||||||||||||||||||||||||||||||
| Full Title: A randomized double-blind placebo-controlled phase II trial of Rucaparib maintenance therapy for patients with locally advanced cervical cancer | |||||||||||||||||||||||||||||||||
| Medical condition: Cancer of uterine cervix | |||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Female | ||||||||||||||||||||||||||||||||
| Trial protocol: SE (Prematurely Ended) | |||||||||||||||||||||||||||||||||
| Trial results: View results | |||||||||||||||||||||||||||||||||
| EudraCT Number: 2012-005198-30 | Sponsor Protocol Number: BBHV.02-2012 | Start Date*: 2013-04-30 |
| Sponsor Name:LAURA TARRATS VELASCO | ||
| Full Title: EFFICACY OF ADMINISTRATION OF HYOSCINE BUTILBROMIDE (BUSCOPAN®) ON PREGNANT WOMEN IN FIRST STAGE OF LABOUR IN CASE OF CERVIX RIGIDITY. (BBH V.04-2013 EUDRACT: 2012-005198-30) | ||
| Medical condition: in case of cervix rigidity determination in first stage of labour, pregnant women will be offered to participate and if they accept they´ll be randomised to test or control group. Placebo or treat... | ||
| Disease: | ||
| Population Age: Adults | Gender: Female | |
| Trial protocol: ES (Ongoing) | ||
| Trial results: (No results available) | ||
| EudraCT Number: 2019-004895-21 | Sponsor Protocol Number: WO42017 | Start Date*: 2020-06-01 |
| Sponsor Name:F. Hoffmann-La Roche Ltd | ||
| Full Title: A PHASE II, SAFETY, AND EFFICACY STUDY OF TIRAGOLUMAB PLUS ATEZOLIZUMAB AND ATEZOLIZUMAB MONOTHERAPY IN PATIENTS WITH METASTATIC AND/OR RECURRENT PD-L1−POSITIVE CERVICAL CANCER. | ||
| Medical condition: Cervical cancer | ||
| Disease: | ||
| Population Age: Adults, Elderly | Gender: Male, Female | |
| Trial protocol: GB (GB - no longer in EU/EEA) FR (Completed) IT (Completed) | ||
| Trial results: (No results available) | ||
| EudraCT Number: 2004-003944-23 | Sponsor Protocol Number: UFK-HEF 5 | Start Date*: 2005-04-20 |
| Sponsor Name:Medical University of Vienna | ||
| Full Title: Acetyl salicylic acid in the treatment of patients with positive margins after surgery for cervical dysplasia grade II-III: A phase II trial | ||
| Medical condition: Cervical intraepithelial neoplasia grade II/III with positive margin after surgery | ||
| Disease: | ||
| Population Age: Adults | Gender: Female | |
| Trial protocol: AT (Prematurely Ended) | ||
| Trial results: View results | ||
| EudraCT Number: 2014-005576-28 | Sponsor Protocol Number: VB-C-01 | Start Date*: 2015-07-13 |
| Sponsor Name:VACCIBODY A.S. | ||
| Full Title: An Exploratory Safety and Immunogenicity Study of Human Papillomavirus (HPV16+) Immunotherapy VB10.16 in Women with High Grade Cervical Intraepithelial Neoplasia (HSIL; CIN 2/3) | ||
| Medical condition: High grade cervical intraepithelial neoplasia (HSIL, CIN 2/3) | ||
| Disease: | ||
| Population Age: Adults, Elderly | Gender: Female | |
| Trial protocol: DE (Completed) | ||
| Trial results: View results | ||
| EudraCT Number: 2013-001249-15 | Sponsor Protocol Number: 314-12-401 | Start Date*: 2013-11-07 | ||||||||||||||||||||||||||||||||||||
| Sponsor Name:Otsuka Novel Products GmbH | ||||||||||||||||||||||||||||||||||||||
| Full Title: A Two-Part Phase 1/2a, Open-Label, Dose-Escalation Study to Evaluate the Tolerability and Preliminary Antitumour Activity of OPB-111001 in Patients with Advanced Cancers that are Poorly Responsive ... | ||||||||||||||||||||||||||||||||||||||
| Medical condition: • Advanced prostate cancer • Advanced epithelial ovarian cancer, advanced squamous cell carcinoma of the cervix, advanced breast cancer, endometrial cancer, and salivary gland cancer that are p... | ||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||||||||||||||||||||||
| Trial protocol: GB (Prematurely Ended) | ||||||||||||||||||||||||||||||||||||||
| Trial results: View results | ||||||||||||||||||||||||||||||||||||||
| EudraCT Number: 2019-001226-10 | Sponsor Protocol Number: 1.0 | Start Date*: 2020-09-29 | |||||||||||
| Sponsor Name:FONDAZIONE POLICLINICO UNIVERSITARIO AGOSTINO GEMELLI IRCCS UNIVERSITA' CATTOLICA DEL SACRO CUORE | |||||||||||||
| Full Title: PHASE II PROSPECTIVE STUDY OF NIRAPARIB IN THE SALVAGE TREATMENT OF PATIENTS WITH METASTATIC/RECURRENT/PERSISTENT UTERINE CERVICAL CARCINOMA: PROOF OF CONCEPT (Translational substudy: Evaluation ... | |||||||||||||
| Medical condition: METASTATIC/RECURRENT/PERSISTENT UTERINE CERVICAL CARCINOMA | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Female | ||||||||||||
| Trial protocol: IT (Prematurely Ended) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
| Download Options: | |
|---|---|
| Number of Trials to download: | |
| Download Content: | |
| Download Format: | |
| Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. | |
Query did not match any studies.
